Elsevier

Journal of Critical Care

Volume 17, Issue 4, December 2002, Pages 240-245
Journal of Critical Care

Occurrence of ventilator-associated pneumonia in mechanically ventilated pediatric intensive care patients during stress ulcer prophylaxis with sucralfate, ranitidine, and omeprazole

https://doi.org/10.1053/jcrc.2002.36761Get rights and content

Purpose: The purpose of the study was to evaluate the effects of sucralfate, ranitidine, and omeprazole use on incidence of ventilatory-associated pneumonia (VAP) and mortality in ventilated pediatric critical care patients.

Materials and Methods: This prospective study was conducted at the pediatric intensive care unit (PICU) between August 2000 and February 2002. A total of 160 patients who needed mechanical ventilation were randomized into 4 groups according to the computergenerated random number table: group (S), (n=38) received sucralfate suspension 60 mg/kg/d in 4 doses via the nasogastric tube that was flushed with 10 mL of sterile water; group (R), (n=42) received ranitidine 2 mg/kg/d intravenously in 4 doses; group (O), (n=38) received omeprazole 1 mg/kg/d intravenously in 2 doses; and group (P), (n=42) did not receive any medication for stress ulcer prophylaxis. Treatment was begun within 6 hours of PICU admission.

Results: Seventy patients (44%) developed VAP.VAP rate was 42% (16 of 38) in the sucralfate group, 48% (20 of 42) in the ranitidine group, 45% (17 of 38) in the omeprazole group, and 41% (17 of 42) in the nontreated group. Overall mortality rate was 22% (35 of 160); it was 21% (8 of 38) in the sucralfate group, 23% (10 of 42) in the ranitidine group, 21% (8 of 38) in the omeprazole group, and 21% (9 of 42) in the nontreated group. Our results did not show any difference in the incidence of VAP and mortality in mechanically ventilated PICU patients treated with ranitidine, omeprazole, or sucralfate, or nontreated subjects (P=.963, confidence interval [Cl]=0.958–0.968; P=.988, Cl=0.985–0.991, respectively). Nine patients (5.6%) had macroscopic bleeding. There was no statistically significant difference in macroscopic bleeding between groups.

Conclusions: Our results did not show any diference in the incidence of VAP, macroscopic stress ulcer bleeding, and mortality in the mechanically ventilated PICU patients treated with ranitidine, omeprazole, or sucralfate, or nontreated subjects. None of the treatment treated group. Because there is insufficient data about stress ulcer prophylaxis and VAP in the pediatric age group, more studies with larger numbers of patients are needed.

References (34)

  • GottliebJE et al.

    Gastrointestinal complications in critically ill patients: The intensivists' overview

    Am J Gastroenterol

    (1986)
  • LacroixJ et al.

    Frequency of upper gastrointestinal bleeding in a pediatric intensive care unit

    Crit Care Med

    (1992)
  • FriedmanCJ et al.

    Prophylaxis of upper gastrointestinal hemorrhage in patients requiring mechanical ventilation

    Crit Care Med

    (1982)
  • CookDJ et al.

    Stress ulcer prophylaxis in critically ill patients: Resolving discordant meta-analyses

    JAMA

    (1996)
  • FeldmanM et al.

    Histamine 2 receptor antagonists: Standard therapy for acid-peptic diseases

    N Engl J Med

    (1990)
  • DriksMR et al.

    Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers: The role of gastric colonization

    N Engl J Med

    (1987)
  • SammloffIM et al.

    Inhibition of peptic activity by sucralfate

    Am J Med

    (1985)
  • Cited by (86)

    • Sucralfate as an Adjunct to Analgesia to Improve Oral Intake in Children With Infectious Oral Ulcers: A Randomized, Double-Blind, Placebo-Controlled Trial

      2021, Annals of Emergency Medicine
      Citation Excerpt :

      Sucralfate, a basic aluminum salt of a sulfated disaccharide, is a topical agent that forms a protective barrier.9 It is commonly used for treating ulcerative diseases of the gastrointestinal tract,10-12 and chemotherapy-induced mucositis13 or managing postoperative oral pain.14-16 The efficacy of sucralfate as a topical analgesic for infectious oral ulcers in children is less well understood.

    • Reassessing the Use of Proton Pump Inhibitors and Histamine-2 Antagonists in Critically Ill Children: A Systematic Review and Meta-Analysis

      2021, Journal of Pediatrics
      Citation Excerpt :

      The administration of PPIs and/or H2RAs was associated with an increased risk of NP compared with no intervention (MHRD, 5.3%; 95% CI, 3.5%-7.0%; P < .001; I2 = 0%). Three studies with a total of 336 234 patients reported mortality (Figure 5, A; available at www.jpeds.com).21,25,29 Stress ulcer prophylaxis was associated with increased risk of all-cause mortality compared with no intervention (MHRD, 2.1%; 95% CI, 2.0%-2.2%; P < .001; I2 = 0%).

    • Aspiration

      2019, Kendig's Disorders of the Respiratory Tract in Children, Ninth Edition
    • 76 - Aspiration

      2019, Kendig's Disorders of the Respiratory Tract in Children
    • Maturation of Motor Function in the Preterm Infant and Gastroesophageal Reflux

      2018, Gastroenterology and Nutrition: Neonatology Questions and Controversies
    View all citing articles on Scopus
    View full text